ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Targeted Therapies + Chemo Show Activity in Recurrent/Metastatic Head And Neck Cancer

by Mark Fuerst • February 1, 2008

  • Tweet
  • Email
Print-Friendly Version

The targeted therapies erlotinib and cetuximab, in combination with standard chemotherapy regimens, are well tolerated and have very encouraging activity in recurrent/metastatic head and neck squamous cell carcinoma, according to two presentations at the American Society of Clinical Oncology (ASCO) 2007 Annual Meeting in Chicago.

You Might Also Like

  • Targeted Therapy a Potential Treatment for Head and Neck Cancer
  • PET Not Ready for Routine Management of Head and Neck Cancer
  • New Treatment for Head and Neck Cancer Means Longer-Lasting Toxicity
  • Management Issues in Recurrent and Metastatic Thyroid Cancer
Explore This Issue
February 2008

Interrupting the epidermal growth factor receptor (EGFR) signaling pathway has shown promise in a variety of cancers, and preclinical data have demonstrated possible synergy with platinums and taxanes, said Edward S. Kim, MD, Assistant Professor of Thoracic/Head and Neck Medical Oncology at the University of Texas M. D. Anderson Cancer Center in Houston. Treatment options for recurrent/metastatic head and neck squamous cell carcinoma are limited.

An M. D. Anderson study of cisplatin and docetaxel showed a response rate of 40% and median survival of 9.6 months. Erlotinib, an EGFR tyrosine kinase inhibitor, had a 4.3% response rate as a single agent in head and neck squamous cell carcinoma. Because of the possible synergy and efficacy, we proposed to study the combination of cisplatin, docetaxel, and erlotinib in advanced head and neck squamous cell carcinoma, Dr. Kim said.

In this open-label, Phase II trial, patients were required to have adequate performance status, measurable disease, and no prior EGFR therapy, and may have received prior induction, concomitant, or adjuvant chemotherapy, but not for recurrent/metastatic disease. Sites of disease included squamous cell head and neck sites excluding nasopharynx.

Treatment included docetaxel at 75 mg/m2 and cisplatin at 75 mg/m2, given intravenously every three weeks for up to six cycles and erlotinib at 150 mg, given orally, daily until progression. All agents were started on the first day, and patients were treated with growth factor support.

The trial has completed accrual of 50 patients, and 47 patients, median age of 57, were available for analysis. The majority had an Eastern Cooperative Oncology Group performance status of 1 (41 patients). Most patients (63%) had locoregional disease. The patients were predominantly smokers, with more than 75% being current or former smokers.

Prior therapy included radiation alone in four patients, surgery and radiation in 20, chemotherapy and radiation in five, and chemotherapy, radiation, and surgery in 13 patients. Six patients were untreated.

Complete responses have been observed in four patients (8%), partial responses in 28 patients (58%), and 13 patients (25%) have stable disease, for an overall response rate of 66% and a disease control rate of 91%. Only three patients had disease progression after two cycles of treatment.

Pages: 1 2 3 4 | Single Page

Filed Under: Departments, Head and Neck, Medical Education, Practice Focus Tagged With: cancer, carcinoma, outcomes, radiation, research, treatmentIssue: February 2008

You Might Also Like:

  • Targeted Therapy a Potential Treatment for Head and Neck Cancer
  • PET Not Ready for Routine Management of Head and Neck Cancer
  • New Treatment for Head and Neck Cancer Means Longer-Lasting Toxicity
  • Management Issues in Recurrent and Metastatic Thyroid Cancer

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Weaning Patients Off of PPIs
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Vertigo in the Elderly: What Does It Mean?
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Podcasts Becoming More Popular Method of Education for Otolaryngologists
    • How to Embrace Optimism in the Midst of the COVID-19 Pandemic
    • Tips on How to Approach Conversations with Patients about the COVID-19 Vaccine
    • Steps You Should Take to Protect Your Voice and Hearing During Telemedicine Sessions
    • Routine Postoperative Adjunct Treatments Unnecessary for Idiopathic Cerebrospinal Fluid Leaks

Polls

Have you spoken with your patients about receiving the COVID-19 vaccine?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.